Cambridge, UK, 18 Feb 2022: o2h Ventures is pleased to announce a SEIS investment into Neucruit, a London based company that has developed an Intelligent lead generation software for clinical trial recruitment that helps sponsors and healthcare professionals reach thousands of potential participants in just one click.

It is the first platform that allows teams to complete digital patient recruiting duties, obtain patient-specific information, get support, and keep patients engaged – all in one place. The technology aggregates real-time data from the over 25 million health-related conversations initiated online everyday to facilitate planning and recruitment in clinical trials. Less than 0.02% of companies were awarded by Innovate UK last year Neucruit was one of them.

The investment was made from the recently launched human health SEIS fund which aims to invest in seed-stage SEIS qualifying companies covering novel drug discovery, enabling services and AI technologies.

Sunil Shah, CEO at o2h Ventures said: “We are very happy to back Neucruit, we have seen in our own portfolio the impact that slow patient recruitment can have on getting new drugs to patients”.

About Neucruit

Neucruit is intelligent software for clinical trial recruitment that redefines patient recruitment. Their technology aggregates real-time data from the over 25 million health-related conversations initiated online everyday to facilitate planning and recruitment in clinical trials. 

They assist biopharmaceutical firms, site teams, and investigators in improving site selection, optimising recruitment materials, and reaching groups that are hard to reach using standard techniques.

For more information, please see – https://neucruit.com/

About o2h ventures

The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit www.o2hventures.com

Media Contact:

Ayushi Vijayvargiya

Marketing Executive

ayushi.vijayvargiya@o2h.com

o2h-ventures